NEWS

On March 28, Haier Biomedical released its 2024 Annual Performance Report, reporting total revenue of RMB 2.284 billion and a return to positive growth. On a quarterly basis, year-over-year revenue growth turned positive in the third quarter and continued to accelerate in the fourth, reaching 10.40% — a clear indicator of gradual recovery. The company's non-storage new industry business segments also demonstrated strong momentum, with an annual growth rate of 21.25%.These segments' contribution to total revenue increased to 45.47%, up 7.93 percentage points from the previous year, positioning them as key drivers of future growth.

During Madagascar's rainy season—marked by raging hurricanes and impassable, muddy roads—Haier Biomedical's local service team braved mountain trails, carrying vaccines by hand and over their shoulders to complete cold chain delivery missions one after another.

Haier Biomedical is proud to announce that a selection of its flagship products has successfully achieved certification under the European Union Medical Device Regulation (EU MDR 2017/745). This milestone underscores the company’s unwavering commitment to safety, performance, and full regulatory compliance across its product portfolio.

On March 19, HB TempCon Aviation, a subsidiary of Haier Biomedical, successfully passed the airworthiness review by the United States Federal Aviation Administration (FAA) for its independently developed Active Temperature Controlled RKN Container, becoming the first and only company in the Asia-Pacific region to receive an FAA Design Approval Letter (LODA) for an active temperature controlled container.

Haier Biomedical has successfully installed 100 HYC-61 smart vaccine refrigerators, 10 HYC-361 smart vaccine refrigerators, and 10 vaccine scanning cabinets across 10 hospitals and more than 10 township clinics in Nakhchivan, Azerbaijan. Equipped with IoT technology, this initiative creates a fully connected ecosystem, integrating people, equipment, and vaccines to build a smart vaccine city network. This ensures comprehensive vaccination safety while significantly advancing local healthcare infrastructure.

On March 7, following a successful product training and strategy session with the Australian partners, Haier Biomedical launched an intensive spring training program for its Southeast Asian distributors, concluding on a high note. The program provided in-depth insights into the company's cutting-edge products through a structured curriculum and practical workshops, enhancing distributors' knowledge and practical application of its solutions, thereby showcasing the company's strong organizational capabilities and commitment to global service excellence.

The management of fentanyl and other controlled substances has long been a critical global issue in medical safety. Recently, global attention on fentanyl control has intensified, fueling discussions on effective strategies for managing these high-risk drugs.

Recently, Haier Biomedical has achieved a new milestone in the higher education sector of Hong Kong and Macau with the successful installation of its first batch of centrifuges at Macau University of Science and Technology (MUST). The company's centrifuges have already been adopted by prestigious institutions, including the University of Hong Kong and the Hong Kong Polytechnic University.

In the biopharmaceutical industry, the transport and storage of temperature-sensitive biosamples and pharmaceuticals—such as blood products, cells, biological tissues, and vaccines—require a consistently stable ultra-low temperature environment to maintain their viability and integrity. This demands exceptional insulation performance and reliability from transport equipment. Recently, Haier Biomedical's CryoBio Biobank Series Liquid Nitrogen Container and Low-Temperature Transport Trolley have gained significant recognition in the Japanese market, earning widespread praise and strong user preference.